PDF(Pubmed)
Abstract：
OBJECTIVE: To analyze, using the medication review program, Revisem®, the prevalence of drug-related problems (DRP) in patients in the province of Valencia who were on active treatment with proton pump inhibitors (PPI) in 2022.
METHODS: Descriptive and retrospective observational study.
METHODS: The pharmacotherapeutic history of 295 patients was analyzed following the criteria proposed by the Pharmaceutical Care Network Europe, using the Revisem® digital platform of the Muy Ilustre Colegio Oficial de Farmacéuticos (MICOF).
RESULTS: The mean age of the patients was 81.8 ± 11.1 years and 66.4% were women. At least one DRP was detected in 97.3% of patients. 46.9% of the DRP analyzed were interactions, of which 29.7% involved a PPI, with omeprazole being the most frequent. DRPs with PPI are significantly related to certain patient conditions and pharmacological groups, such as female sex, age over 54 years and polypharmacy.
CONCLUSIONS: The application of the Revisem® digital platform allows the detection of a high prevalence of DRP at the provincial level. The application of new technological tools to detect the prevalence of DRP is essential to optimize patient treatments.
METHODS: Descriptive and retrospective observational study.
METHODS: The pharmacotherapeutic history of 295 patients was analyzed following the criteria proposed by the Pharmaceutical Care Network Europe, using the Revisem® digital platform of the Muy Ilustre Colegio Oficial de Farmacéuticos (MICOF).
RESULTS: The mean age of the patients was 81.8 ± 11.1 years and 66.4% were women. At least one DRP was detected in 97.3% of patients. 46.9% of the DRP analyzed were interactions, of which 29.7% involved a PPI, with omeprazole being the most frequent. DRPs with PPI are significantly related to certain patient conditions and pharmacological groups, such as female sex, age over 54 years and polypharmacy.
CONCLUSIONS: The application of the Revisem® digital platform allows the detection of a high prevalence of DRP at the provincial level. The application of new technological tools to detect the prevalence of DRP is essential to optimize patient treatments.
摘要：
目的：分析，使用药物审查计划，Revisem®,2022年瓦伦西亚省接受质子泵抑制剂(PPI)积极治疗的患者的药物相关问题(DRP)患病率.
方法：描述性和回顾性观察性研究。
方法：按照欧洲药学监护网络提出的标准，对295例患者的药物治疗史进行了分析。使用MuyIlustreColegioOficialdeFarméuticos（MICOF）的Revisem®数字平台。
结果：患者的平均年龄为81.8±11.1岁，66.4%为女性。在97.3%的患者中检测到至少一个DRP。分析的DRP中有46.9%是相互作用，其中29.7%涉及PPI，奥美拉唑是最常见的。PPI的DRP与某些患者状况和药物组显着相关，比如女性，年龄在54岁以上和多药房。
结论：使用Revisem®数字平台可以检测到省级DRP的高患病率。应用新技术工具来检测DRP的患病率对于优化患者治疗至关重要。
方法：描述性和回顾性观察性研究。
方法：按照欧洲药学监护网络提出的标准，对295例患者的药物治疗史进行了分析。使用MuyIlustreColegioOficialdeFarméuticos（MICOF）的Revisem®数字平台。
结果：患者的平均年龄为81.8±11.1岁，66.4%为女性。在97.3%的患者中检测到至少一个DRP。分析的DRP中有46.9%是相互作用，其中29.7%涉及PPI，奥美拉唑是最常见的。PPI的DRP与某些患者状况和药物组显着相关，比如女性，年龄在54岁以上和多药房。
结论：使用Revisem®数字平台可以检测到省级DRP的高患病率。应用新技术工具来检测DRP的患病率对于优化患者治疗至关重要。
